» Articles » PMID: 37200108

Host Genetic Background is a Barrier to Broadly Effective Vaccine-mediated Protection Against Tuberculosis

Abstract

Heterogeneity in human immune responses is difficult to model in standard laboratory mice. To understand how host variation affects Bacillus Calmette Guerin-induced (BCG-induced) immunity against Mycobacterium tuberculosis, we studied 24 unique collaborative cross (CC) mouse strains, which differ primarily in the genes and alleles they inherit from founder strains. The CC strains were vaccinated with or without BCG and challenged with aerosolized M. tuberculosis. Since BCG protects only half of the CC strains tested, we concluded that host genetics has a major influence on BCG-induced immunity against M. tuberculosis infection, making it an important barrier to vaccine-mediated protection. Importantly, BCG efficacy is dissociable from inherent susceptibility to tuberculosis (TB). T cell immunity was extensively characterized to identify components associated with protection that were stimulated by BCG and recalled after M. tuberculosis infection. Although considerable diversity is observed, BCG has little impact on the composition of T cells in the lung after infection. Instead, variability is largely shaped by host genetics. BCG-elicited protection against TB correlated with changes in immune function. Thus, CC mice can be used to define correlates of protection and to identify vaccine strategies that protect a larger fraction of genetically diverse individuals instead of optimizing protection for a single genotype.

Citing Articles

CD226 identifies effector CD8 T cells during tuberculosis and costimulates recognition of -infected macrophages.

Shinkawa T, Chang E, Rakib T, Cavallo K, Lai R, Behar S bioRxiv. 2025; .

PMID: 39896604 PMC: 11785225. DOI: 10.1101/2025.01.22.634303.


Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals.

Lyu J, Narum D, Baldwin S, Larsen S, Bai X, Griffith D Front Immunol. 2024; 15:1427559.

PMID: 39717773 PMC: 11663721. DOI: 10.3389/fimmu.2024.1427559.


The chosen few: isolates for IMPAc-TB.

Larsen S, Abdelaal H, Plumlee C, Cohen S, Kim H, Barrett H Front Immunol. 2024; 15:1427510.

PMID: 39530100 PMC: 11551615. DOI: 10.3389/fimmu.2024.1427510.


Immune correlates of protection as a game changer in tuberculosis vaccine development.

Wang J, Fan X, Hu Z NPJ Vaccines. 2024; 9(1):208.

PMID: 39478007 PMC: 11526030. DOI: 10.1038/s41541-024-01004-w.


Host and pathogen genetic diversity shape vaccine-mediated protection to .

Cohen S, Plumlee C, Engels L, Mai D, Murray T, Jahn A Front Immunol. 2024; 15:1427846.

PMID: 39007152 PMC: 11239334. DOI: 10.3389/fimmu.2024.1427846.


References
1.
Roederer M, Nozzi J, Nason M . SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A. 2011; 79(2):167-74. PMC: 3072288. DOI: 10.1002/cyto.a.21015. View

2.
Kipnis A, Irwin S, Izzo A, Basaraba R, Orme I . Memory T lymphocytes generated by Mycobacterium bovis BCG vaccination reside within a CD4 CD44lo CD62 ligand(hi) population. Infect Immun. 2005; 73(11):7759-64. PMC: 1273888. DOI: 10.1128/IAI.73.11.7759-7764.2005. View

3.
Manet C, Simon-Loriere E, Jouvion G, Hardy D, Prot M, Conquet L . Genetic Diversity of Collaborative Cross Mice Controls Viral Replication, Clinical Severity, and Brain Pathology Induced by Zika Virus Infection, Independently of . J Virol. 2019; 94(3). PMC: 7000970. DOI: 10.1128/JVI.01034-19. View

4.
Roy A, Eisenhut M, Harris R, Rodrigues L, Sridhar S, Habermann S . Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ. 2014; 349:g4643. PMC: 4122754. DOI: 10.1136/bmj.g4643. View

5.
Nemeth J, Olson G, Rothchild A, Jahn A, Mai D, Duffy F . Contained Mycobacterium tuberculosis infection induces concomitant and heterologous protection. PLoS Pathog. 2020; 16(7):e1008655. PMC: 7365393. DOI: 10.1371/journal.ppat.1008655. View